PhenomeX

PhenomeX’s Beacon® Technology Enables Early Identification of Potent Omicron-Neutralizing Antibodies

by

EMERYVILLE, Calif., June 13, 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the Company’s technology was recently featured in a groundbreaking study published in Cell Reports titled “Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence” that has revealed the remarkable efficacy of vaccines in generating … Read more

PhenomeX neemt deel aan Antibody Engineering & Therapeutics Europe 2023

by

Het Bedrijf toont zijn onlangs gelanceerde Beacon Select™-technologie voor de ontdekking van antilichamen en de ontwikkeling van cellijnen EMERYVILLE, Californië, 5 juni 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), het bedrijf voor functionele celbiologie, heeft vandaag bekendgemaakt van 6-8 juni 2023 in het Postillion Hotel Amsterdam aan de Antibody Engineering & Therapeutics (AE&T) Europe 2023 … Read more

PhenomeX Launches Beacon Quest™ Optofluidic System with Opto® T Cell Profiling Workflows

by

Beacon Quest designed with affordable two-chip optofluidic system to accelerate the pace of scientific discovery across academic, non-profit, and government research including comprehensive single T Cell profiling, for precision immunotherapy translational research and accelerated development EMERYVILLE, Calif., June 5, 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch … Read more

PhenomeX to Participate in Antibody Engineering & Therapeutics Europe 2023

by

Company to feature its recently launched Beacon Select™ technology for antibody discovery and cell line development EMERYVILLE, Calif., June 5, 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced its participation in the Antibody Engineering & Therapeutics (AE&T) Europe 2023 from 6-8 June 2023 at the Postillion Hotel Amsterdam. AE&T is … Read more

PhenomeX nimmt an der Antibody Engineering & Therapeutics Europe 2023 teil

by

Das Unternehmen stellt seine kürzlich eingeführte Beacon Select™-Technologie für die Entdeckung von Antikörpern und die Entwicklung von Zelllinien vor  EMERYVILLE, Kalifornien, 5. Juni 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), das Unternehmen für funktionelle Zellbiologie, gab heute seine Teilnahme an der Antibody Engineering & Therapeutics (AE&T) Europe 2023 vom 6.-8. Juni 2023 im Postillion Hotel … Read more